We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$127B
1-Year Est. Return
46.06%
This Fund
S&P 500
This Quarter
Est. Return
-12.49%
1 Year Est. Return
+46.06%
3 Year Est. Return
+142.12%
5 Year Est. Return
+190.33%
10 Year Est. Return
+787.47%
AUM
$48.6B
AUM Growth
-$4.2B
(-8%)
Cap. Flow
+$2.77B
Cap. Flow
% of AUM
5.69%
Top 10 Holdings %
Top 10 Hldgs %
10.29%
Holding
4,108
New
835
Increased
963
Reduced
740
Closed
743
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$340M |
| 2 |
Bank of America
BAC
|
+$302M |
| 3 |
Cigna
CI
|
+$294M |
| 4 |
TSMC
TSM
|
+$275M |
| 5 |
Union Pacific
UNP
|
+$256M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verizon
VZ
|
+$426M |
| 2 |
S&P Global
SPGI
|
+$413M |
| 3 |
Booking.com
BKNG
|
+$264M |
| 4 |
Comcast
CMCSA
|
+$256M |
| 5 |
Teleflex
TFX
|
+$241M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.67% |
| 2 | Financials | 16.99% |
| 3 | Technology | 16.42% |
| 4 | Miscellaneous | 11.36% |
| 5 | Consumer Discretionary | 9.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KZR
576
DELISTED
Kezar Life Sciences
KZR
| $15.8M | 0.03% |
190,852
+145,302
| +319% | +$12.8M |
|
|
MACC
577
DELISTED
Mission Advancement Corp.
MACC
| $15.7M | 0.03% |
1,609,629
| – | – |
|
|
IS
578
DELISTED
ironSource Ltd.
IS
| $15.7M | 0.03% |
6,602,255
+4,031,175
| +157% | +$13.5M |
|
579
PUT
VanEck Gold Miners ETF
GDX
$29.9B
| $15.7M | 0.03% |
573,200
-846,100
| -60% | -$28.5M |
|
580
Cameco
CCJ
$44.4B
| $15.7M | 0.03% |
746,221
+338,482
| +83% | +$8.54M |
|
|
ZING
581
DELISTED
FTAC Zeus Acquisition Corp. Class A Common Stock
ZING
| $15.7M | 0.03% |
1,585,787
+115,787
| +8% | +$1.14M |
|
582
Sea Limited
SE
$69.4B
| $15.7M | 0.03% |
234,394
+215,221
| +1,123% | +$18.3M |
|
|
MTVC
583
DELISTED
Motive Capital Corp II
MTVC
| $15.7M | 0.03% |
1,583,457
| – | – |
|
584
L3Harris
LHX
$47.6B
| $15.6M | 0.03% |
64,687
-214,788
| -77% | -$51.8M |
|
585
PUT
Moderna
MRNA
$56B
| $15.6M | 0.03% |
109,400
+72,900
| +200% | +$10.4M |
|
586
Alibaba
BABA
$280B
| $15.5M | 0.03% |
136,691
+22,455
| +20% | +$2.2M |
|
587
Oxford Industries
OXM
$473M
| $15.5M | 0.03% |
174,892
+80,351
| +85% | +$7.21M |
|
588
Ramaco Resources Class A
METC
$794M
| $15.5M | 0.03% |
1,218,779
+716,550
| +143% | +$10.8M |
|
|
HR
589
DELISTED
Healthcare Realty Trust Incorporated
HR
| $15.5M | 0.03% |
569,133
+529,916
| +1,351% | +$14.8M |
|
590
IPG Photonics
IPGP
$3.38B
| $15.5M | 0.03% |
164,233
+130,552
| +388% | +$12.9M |
|
591
Evercore
EVR
$11.4B
| $15.4M | 0.03% |
164,942
-25,460
| -13% | -$2.71M |
|
|
GFX
592
DELISTED
Golden Falcon Acquisition Corp.
GFX
| $15.4M | 0.03% |
1,567,322
| – | – |
|
|
NFYS
593
DELISTED
Enphys Acquisition Corp.
NFYS
| $15.4M | 0.03% |
1,601,824
| – | – |
|
|
SCLE
594
DELISTED
Broadscale Acquisition Corp. Class A common stock
SCLE
| $15.4M | 0.03% |
1,570,668
| – | – |
|
|
HIGA
595
DELISTED
H.I.G. Acquisition Corp.
HIGA
| $15.4M | 0.03% |
1,554,650
| – | – |
|
596
Church & Dwight Co
CHD
$22.9B
| $15.4M | 0.03% |
165,861
+128,895
| +349% | +$12.2M |
|
|
FOUN
597
DELISTED
Founder SPAC Class A Ordinary Shares
FOUN
| $15.3M | 0.03% |
1,523,697
| – | – |
|
598
Sempra
SRE
$55.9B
| $15.3M | 0.03% |
+203,862
| New | +$16.4M |
|
599
Maravai LifeSciences
MRVI
$1.07B
| $15.3M | 0.03% |
538,356
+37,144
| +7% | +$1.18M |
|
|
ROSS
600
DELISTED
Ross Acquisition Corp II
ROSS
| $15.3M | 0.03% |
1,556,657
+31,324
| +2% | +$307K |
|
Similar funds
Marshall Wace's Q2 2022 Portfolio in Review
As of Q2 2022, Marshall Wace held 4,108 positions worth $48.6B, down 8% from $52.8B the previous quarter. Its ten largest holdings account for 10% of the portfolio.
Marshall Wace deployed $2.77B of net new capital in Q2 2022, opening 835 new positions and adding to 963 existing holdings. Its largest new stake was Eli Lilly: 1,133,393 shares worth $367M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Verizon, an estimated $426M trimmed.
- Marshall Wace's largest Q2 2022 buy was Eli Lilly: 1,133,393 shares worth $367M.
- Marshall Wace added most to Bank of America in Q2 2022, an estimated $302M increase.
- Marshall Wace's biggest Q2 2022 reduction was Verizon, cutting an estimated $426M.
- Marshall Wace fully exited Teleflex in Q2 2022, selling an estimated $241M.
- Marshall Wace's ten largest holdings make up 10% of its $48.6B portfolio in Q2 2022.
- Marshall Wace opened 835 new positions and closed 743 in Q2 2022.
- Marshall Wace's portfolio value fell 8% quarter-over-quarter to $48.6B.
Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.